#United States #Chicago #Sapience Therapeutics #ST316 #Lucicebtide

Sapience Therapeutics to Present Multitude of Cancer Research Findings at AACR 2025

Sapience Therapeutics, Inc., a clinical-stage biotechnology firm, is set to present its pioneering research on peptide therapeutics aimed at tackling cancer at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2025, scheduled to take place from April 25 to April 30 in Chicago, Illinois. This event marks a significant opportunity for the company to share its findings with leading experts in the field of oncology.

The firm will deliver four poster presentations that delve into the non-clinical results of its various clinical programs, notably its lead candidates: lucicebtide and ST316. Both are classified as first-in-class antagonists targeting oncogenic pathways in cancer biology. Additionally, research on the preclinical Fra1 antagonist peptide (FraAP) program will be highlighted, showcasing its potential to influence cancer treatment strategies.

Exciting Findings and Presentations

Among the highlights are findings related to lucicebtide and its role in synergizing with molecularly targeted therapies. The first poster, titled “The clinical C/EBPβ antagonist peptide lucicebtide synergizes with molecularly targeted therapies in GBM,” will discuss how lucicebtide can result in significant improved outcomes when paired with therapies traditionally ineffective for glioblastoma (GBM). The findings emphasize the interaction between lucicebtide and EGFR inhibitors, suggesting a synthetic lethal effect, particularly vital for conditions where other treatments have faltered.

The second presentation focuses on the FraAP program, aiming to suppress the activator protein 1 (AP-1) complex, which plays a crucial role in oncogenic signal transduction. The poster titled “FraAP, a peptide antagonist against the AP-1 transcription factor complex, demonstrates cancer cell cytotoxicity…” suggests substantial tumor growth inhibition in preclinical head and neck squamous cell carcinoma models, reinforcing the compound's potential anti-cancer properties.

Exploring ST316’s Mechanism of Action

Further, the presentation titled “An ex vivo organoid study to identify biomarkers of sensitivity to ST316” discusses how the beta-catenin antagonist, ST316, plays a critical role in the molecular landscape of colorectal cancer. Research shows that genetic profiles can predict patient responsiveness to ST316, especially in cases involving specific mutations. This insight could pave the way for personalized treatment approaches in oncology.

Lastly, the team will present results under the poster titled “Reprogramming of MDSCs by ST316…”, demonstrating ST316’s capacity to modulate the immune landscape by inhibiting the activity of myeloid-derived suppressor cells (MDSCs) which typically promote tumor growth and suppress anti-tumor immunity. Combining this treatment with traditional chemotherapy increased its efficacy, illustrating the potential for enhanced therapeutic strategies.

About Sapience and Its Contributions to Cancer Research

Sapience Therapeutics stands at the forefront of cancer research, pushing boundaries with its innovative approach to peptide therapeutics. The company prioritizes addressing oncogenic and immune dysregulation in cancer, striving to offer solutions where traditional therapies frequently fall short. Their proprietary pipelines, named SPEARs™—Stabilized Peptides Engineered Against Regulation—aim to target previously considered undruggable transcription factors, highlighting significant advancements in biotechnology.

As they prepare to showcase their findings at the AACR Annual Meeting 2025, interest peaks among oncologists and researchers eager to explore the promising landscape of novel cancer therapies. With a commitment to improving outcomes for cancer patients, Sapience Therapeutics is not just participating in a conference; they're looking to inspire the future of cancer care.

For additional insights and detailed information, attendees and interested stakeholders can engage with Sapience through their official website prior to the meeting.